Ligand Pharmaceuticals Share Price Today
(NASDAQ: LGND)

Name: Ligand Pharmaceuticals Share Price Today (NASDAQ: LGND) - Ligand Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Ligand Pharmaceuticals share price is $115.41 & ₹10,037.09 as on 6 Mar 2025, 2.30 'hrs' IST

$115.41

▲

0.15

(0.13%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Ligand Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Ligand Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ligand Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Ligand Pharmaceuticals share price movements

Today's Low: $113.24
Today's High: $117.58
$115.41
1.88%
Downside
Day's Volatility :3.7%
Upside
1.85%
52 Weeks Low: $67.72
52 Weeks High: $129.90
$115.41
41.32%
Downside
52 Weeks Volatility :47.87%
Upside
11.15%

Ligand Pharmaceuticals (LGND) Returns

Period	Ligand Pharmaceuticals Incorporated	Sector (Health Care)	Index (Russel 2000)
3 Months	-6.68%	2.1%	0.0%
6 Months	11.74%	-4.1%	0.0%
1 Year	58.52%	2.2%	0.0%
3 Years	17.72%	11.8%	-11.6%

Ligand Pharmaceuticals (LGND) Key Statistics

in dollars & INR

Previous Close	$115.26
Open	$115.4
Today's High	$117.58
Today's Low	$113.235
Market Capitalization	$2.1B
Today's Volume	$57.9K
52 Week High	$129.9
52 Week Low	$67.72
Revenue TTM	$167.1M
EBITDA	$58.5M
Earnings Per Share (EPS)	$-0.22
Profit Margin	-2.41%
Quarterly Earnings Growth YOY	1.03%
Return On Equity TTM	-0.53%

How to invest in Ligand Pharmaceuticals Stock (LGND) from India?

It is very easy for Indian residents to invest directly in Ligand Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ligand Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ligand Pharmaceuticals or LGND on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ligand Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ligand Pharmaceuticals shares which would translate to 0.008 fractional shares of Ligand Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ligand Pharmaceuticals, in just a few clicks!

Returns in Ligand Pharmaceuticals (LGND) for Indian investors in Rupees

The Ligand Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Ligand Pharmaceuticals investment value today

Current value as on today

₹1,63,689

Returns

₹63,689

(+63.69%)

Returns from Ligand Pharmaceuticals Stock

₹58,726 (+58.73%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Ligand Pharmaceuticals (LGND)

-30%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Ligand Pharmaceuticals Stock from India on INDmoney has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Ligand Pharmaceuticals

BlackRock Inc
15.59%
Vanguard Group Inc
11.04%
HHG PLC
5.37%
Macquarie Group Ltd
4.68%
State Street Corp
3.94%
Dimensional Fund Advisors, Inc.
3.83%

Analyst Recommendation on Ligand Pharmaceuticals

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Ligand Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ligand Pharmaceuticals Stock (LGND)

What analysts predicted

Upside of 25.1%

Target:

$144.38

Current:

$115.41

Insights on Ligand Pharmaceuticals Stock (Ticker Symbol: LGND)

Price Movement
In the last 1 year, LGND stock has moved up by 55.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 51.81M → 42.81M (in $), with an average decrease of 17.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -7.17M → -31.08M (in $), with an average decrease of 333.5% per quarter
LGND vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 6.5%
LGND vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 28.8%
Price to Sales
ForLGND every $1 of sales, investors are willing to pay $12.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

LGND Ligand Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$120.3M	↓ 52.17%
Net Income	$629.3M	↑ 339.09%
Net Profit Margin	523.19%	↑ 466.19%

	FY20	Y/Y Change
Revenue	$186.4M	↑ 54.98%
Net Income	$-3.0M	↓ 100.47%
Net Profit Margin	-1.6%	↓ 524.79%

	FY21	Y/Y Change
Revenue	$277.1M	↑ 48.66%
Net Income	$57.1M	↓ 2014.17%
Net Profit Margin	20.62%	↑ 22.22%

	FY22	Y/Y Change
Revenue	$196.2M	↓ 29.19%
Net Income	$-5.2M	↓ 109.13%
Net Profit Margin	-2.66%	↓ 23.28%

	FY23	Y/Y Change
Revenue	$131.3M	↓ 33.09%
Net Income	$52.2M	↓ 1099.31%
Net Profit Margin	39.72%	↑ 42.38%

	FY24	Y/Y Change
Revenue	$167.1M	↑ 27.28%
Net Income	$9.1M	↓ 82.61%
Net Profit Margin	5.43%	↓ 34.29%

	Q3 FY23	Q/Q Change
Revenue	$32.9M	↑ 24.66%
Net Income	$-12.8M	↓ 658.6%
Net Profit Margin	-38.92%	↓ 47.61%

	Q4 FY23	Q/Q Change
Revenue	$28.1M	↓ 14.5%
Net Income	$18.2M	↓ 242.18%
Net Profit Margin	64.72%	↑ 103.64%

	Q1 FY24	Q/Q Change
Revenue	$31.0M	↑ 10.24%
Net Income	$86.1M	↑ 373.6%
Net Profit Margin	278.07%	↑ 213.35%

	Q2 FY24	Q/Q Change
Revenue	$41.5M	↑ 34.07%
Net Income	$-51.9M	↓ 160.26%
Net Profit Margin	-124.99%	↓ 403.06%

	Q3 FY24	Q/Q Change
Revenue	$51.8M	↑ 24.76%
Net Income	$-7.2M	↓ 86.18%
Net Profit Margin	-13.84%	↑ 111.15%

	Q4 FY24	Q/Q Change
Revenue	$42.8M	↓ 17.37%
Net Income	$-31.1M	↑ 333.46%
Net Profit Margin	-72.62%	↓ 58.78%

	FY19	Y/Y Change
Profit	$108.9M	↓ 55.56%

	FY20	Y/Y Change
Profit	$156.0M	↑ 43.2%

	FY21	Y/Y Change
Profit	$215.0M	↑ 37.79%

	FY22	Y/Y Change
Profit	$143.4M	↓ 33.28%

	FY23	Y/Y Change
Profit	$96.3M	↓ 32.88%

	FY24	Y/Y Change
Profit	$167.1M	↑ 73.62%

	Q3 FY23	Q/Q Change
Profit	$29.4M	↑ 18.97%

	Q4 FY23	Q/Q Change
Profit	$26.4M	↓ 10.03%

	Q1 FY24	Q/Q Change
Profit	$19.9M	↓ 24.69%

	Q2 FY24	Q/Q Change
Profit	$30.4M	↑ 52.53%

	Q3 FY24	Q/Q Change
Profit	$39.3M	↑ 29.47%

	Q4 FY24	Q/Q Change
Profit	$42.8M	↑ 8.89%

	FY19	Y/Y Change
Operating Cash Flow	$-29.3M	↓ 115.12%
Investing Cash Flow	$466.9M	↓ 210.31%
Financing Cash Flow	$-485.2M	↓ 247.65%

	FY20	Y/Y Change
Operating Cash Flow	$54.6M	↓ 286.07%
Investing Cash Flow	$231.6M	↓ 50.39%
Financing Cash Flow	$-310.5M	↓ 35.99%

	FY21	Y/Y Change
Operating Cash Flow	$78.8M	↑ 44.36%
Investing Cash Flow	$30.5M	↓ 86.82%
Financing Cash Flow	$-137.8M	↓ 55.64%

	FY22	Y/Y Change
Operating Cash Flow	$137.9M	↑ 74.94%
Investing Cash Flow	$163.6M	↑ 436.07%
Financing Cash Flow	$-276.0M	↑ 100.34%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-82.0K	↓ 100.24%
Investing Cash Flow	$7.6M	↓ 28.37%
Financing Cash Flow	$-67.8M	↑ 8642.84%

Ligand Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Ligand Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ligand Pharmaceuticals (LGND) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ligand Pharmaceuticals Incorporated	0.44%	11.74%	58.52%	17.72%	21.83%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ligand Pharmaceuticals Incorporated	46.27	NA	1.53	6.1	-0.01	0.02	NA	43.77
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ligand Pharmaceuticals Incorporated	Buy	$2.1B	21.83%	46.27	-2.41%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Organization	Ligand Pharmaceuticals
Employees	0
CEO	Mr. Scott M. Plesha
Industry	Health Technology

Management People of Ligand Pharmaceuticals

Name	Title
Mr. Todd C. Davis Ph.D.	Director
Mr. Octavio Espinoza	Chief Financial Officer
Mr. Andrew T. Reardon J.D.	Chief Legal Officer
Mr. Paul J. Hadden	Senior Vice President of Investments & Business Development
Dr. Keith Marschke Ph.D.	Senior Vice President of Biology & Scientific Affairs
Dr. Vincent D. Antle Ph.D.	Senior Vice President of Technical Operations & QA - Capitsol
Mr. Patrick Lucy	Senior VP & CBO Protein Expression Business
Dr. Karen R. Reeves M.D.	Senior VP of Investments & Head of Clinical Strategy
Mr. Richard B. Baxter	Senior VP of Investment Operation
Mr. Scott M. Plesha	CEO of Pelthos Therapeutics

Important FAQs about investing in LGND Stock from India :

What is Ligand Pharmaceuticals share price today?

Ligand Pharmaceuticals share price today stands at $115.41, Open: $115.40 ; Previous Close: $115.26 ; High: $117.58 ; Low: $113.24 ; 52 Week High: $129.90 ; 52 Week Low: $67.72.

The stock opens at $115.40, after a previous close of $115.26. The stock reached a daily high of $117.58 and a low of $113.24, with a 52-week high of $129.90 and a 52-week low of $67.72.

Can Indians buy Ligand Pharmaceuticals shares?

Yes, Indians can invest in the Ligand Pharmaceuticals (LGND) from India.

With INDmoney, you can buy Ligand Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ligand Pharmaceuticals at zero transaction cost.

How can I buy Ligand Pharmaceuticals shares from India?

It is very easy to buy Ligand Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ligand Pharmaceuticals (LGND) be purchased?

Yes, you can buy fractional shares of Ligand Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Ligand Pharmaceuticals stocks?

To start investing in Ligand Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.